Durable Response with Trabectedin in A Patient with High-Grade Myxoid Liposarcoma and Orbital Metastases

Background: High-grade Myxoid Liposarcoma (MLPS) has a high metastatic risk. Besides pulmonary metastasis, as in other soft-tissue sarcoma, MLPS shows a characteristic capacity of developing distant metastasis in other body sites, such as abdominal cavity/retroperitoneum, soft part, and bone. Orbital metastases are exceedingly rare in MLPS. In patients with advanced MLPS not amenable with local therapies, systemic chemotherapy remains the backbone treatment. Trabectedin has become an interesting therapeutic option for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Given the exceptional nature of orbital Liposarcoma (LPS) secondary to MLPS, the use of trabectedin in these patients has not been yet elucidated.

Case Presentations: Here, we report the case of a patient with high-grade MLPS and orbital metastases who was successfully treated with trabectedin. The patient achieved very prolonged stable disease, during 77 cycles of trabectedin therapy and with a manageable safety profile with no severe adverse events detected.

Conclusion: Our results additionally confirm that trabectedin enable a long-term therapy conferring relevant disease control with a manageable safety profile and without cumulative toxicities.